Novartis Animal Health Canada Inc., 2000 Argentia Road, Suite 400, Plaza 3, CDN- Mississauga, Ontario L5N1V9 Canada
The objective of this study was to compare the serological responses in cattle initially vaccinated with a modified-live virus (MLV) vaccine containing infectious bovine rhinotracheitis (IBR) virus, parainfluenza-3 (PI3) virus, bovine viral diarrhea virus type 1 (BVDV1), bovine viral diarrhea virus type 2 (BVDV2), and bovine respiratory syncytial (BRS) virus antigens, and subsequently re-vaccinated with either the same MLV vaccine or an oil-adjuvanted, inactivated vaccine containing the same viral antigens.
A group of 145 nursing calves received a MLV vaccine containing IBR, PI3, BVDV1, BVDV2, and BRSV at one to two months of age. The calves were re-vaccinated with the same MLV vaccine at weaning, three-and-a-half months later. Approximately five months later, 45 of these animals were randomly selected and assigned to one of three treatment groups. Twenty calves received an oil-adjuvanted, inactivated vaccine (IBR, PI3, BVDV1, BVDV2, BRSV); 20 received the same MLV vaccine that they had received as calves (IBR, PI3, BVDV1, BVDV2, BRSV); and five controls received the MLV sterile diluent.
Following final vaccination, the animals receiving the oil-adjuvanted, inactivated vaccine had the highest titer response (P<0.05) for IBRV, BRSV, BVDV1, and BVDV2.
Keywords: bovine, vaccination, virus vaccine, anamnestic response
Royan G: Bov Pract 43:44-50, 2009.